ACAD — Acadia Pharmaceuticals Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual balance sheet for Acadia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	632	521	417	439	756
Net Total Accounts Receivable
Net Total Receivables	50.3	65.3	63.1	102	105
Total Inventory
Prepaid Expenses
Total Current Assets	718	618	508	616	938
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	56.4	66.3	61.6	56.5	50.8
Net Intangible Assets
Other Long Term Assets
Total Assets	783	700	588	749	1,188
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Current Liabilities	106	96.1	126	254	395
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	156	159	187	317	455
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	627	541	400	432	733
Total Liabilities & Shareholders' Equity	783	700	588	749	1,188
Total Common Shares Outstanding